SCHEMBL2736889

SCHEMBL2736889

CCCCn1cc(-c2cc(Cl)ccc2Cl)cc(C(=O)NCc2ccc(F)cc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.44
PDE10A Q9Y233 1/20 0.44
CNR1 P21554 8/20 0.43
CNR2 P34972 5/20 0.43
RXFP1 Q9HBX9 2/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
LIPG Q9Y5X9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736883 0.93 CNR1 (0.50) PTGER4PDE10ACNR1CNR2RXFP1
SCHEMBL2736885 0.91 CNR1 (0.52) CNR1CNR2POLBALDH1A1LMNA
SCHEMBL2736820 0.85 CNR1 (0.50) PDE10ACNR1CNR2RXFP1POLB
SCHEMBL2736881 0.83 CNR1 (0.52) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL2736844 0.83 CNR2 (0.52) PDE10ACNR1CNR2RXFP1POLB
SCHEMBL2736808 0.83 CNR1 (0.48) PDE10ACNR1CNR2RXFP1POLB
SCHEMBL2736835 0.83 CNR2 (0.47) PDE10ACNR1CNR2RXFP1POLB
SCHEMBL2736854 0.82 CNR1 (0.48) PDE10ACNR1CNR2RXFP1POLB
SCHEMBL2736888 0.82 LMNA (0.57) CNR1CNR2POLBALDH1A1LMNA
SCHEMBL2736824 0.82 PDE10A (0.55) PDE10ACNR1CNR2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R PTGER4 145/4885PDE10A 3728/4885CNR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.